Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma - Wikidata - wikimedia - TriplyDB

Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma

Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma

http://www.wikidata.org/entity/Q39966334

about

The role of Src in solid tumors Tumor and stromal-based contributions to head and neck squamous cell carcinoma invasion Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells.Dual inhibition of EGFR at protein and activity level via combinatorial blocking of PI4KIIα as anti-tumor strategy.Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma.Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function Elevated c-Src and c-Yes expression in malignant skin cancers Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer Overexpression of Csk-binding protein decreases growth, invasion, and migration of esophageal carcinoma cells by controlling Src activation.Emerging drugs to treat squamous cell carcinomas of the head and neck.Src family kinases and paclitaxel sensitivity.Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting Molecular parameters of head and neck cancer metastasis.PET imaging of EGF receptors using [18F]FBEM-EGF in a head and neck squamous cell carcinoma model.Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor.Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies.Src-signaling interference impairs the dissemination of blood-borne tumor cells Insulin growth factor 1 like receptor (IGF-1R).c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met.Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).Dasatinib Inhibits DNA Repair after Radiotherapy Specifically in pSFK-Expressing Tumor Areas in Head and Neck Xenograft Tumors.Integrin and growth factor receptor alliance in angiogenesis.Targeting EGFR resistance networks in head and neck cancer.Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.Antitumor activity of 7RH, a discoidin domain receptor 1 inhibitor, alone or in combination with dasatinib exhibits antitumor effects in nasopharyngeal carcinoma cells.Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3 Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop.Emerging molecular targeted therapies in the treatment of head and neck cancer.GRIM-19 mutations fail to inhibit v-Src-induced oncogenesis.Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma.Molecular biology of squamous cell carcinoma of the head and neck: relevance and therapeutic implications.Pharmacotherapy for squamous-cell carcinoma of the head and neck.

P2860

Q24616659-8F5E760A-E606-4BA9-B1C2-1E5292EF1272 Q26825164-5B98DD51-87F4-4C2B-AB80-1DE595EC0E2C Q27851586-2EC8C4D0-8E64-41A2-B01B-F222323A4035 Q30424531-AB60591E-F950-4A05-9088-048D145B9A08 Q33632845-1C0CB83E-8553-4285-8E71-1E714AEEB500 Q33737298-3B61AA5C-F445-4D7B-ABCE-E451287C7BA6 Q33767100-0F4EE73B-3AF1-48BF-940B-26572FBB3783 Q33873546-4CC71360-6A3A-4CD8-8809-C5F9D30C66EC Q34114252-7E2092BF-B61D-4FE0-9342-B44237CC06FF Q34283737-FE93CCD1-0BF1-400D-A504-E84293DBCED4 Q34480200-6261345D-424C-4520-9C22-00CF63B2096D Q34578584-E54A4EFE-9043-4AED-9AB8-FF80EEDDC2EB Q34622547-5B48D2A9-EDEA-4898-872A-183596E6CBDB Q35069465-3DADE8E0-0F00-4B87-9EB6-5113B58D56E8 Q35098322-B422DB98-8303-44BC-B6BF-B0002C649F1C Q35214722-24E8C31B-F965-4416-9978-4E55B114F998 Q35434274-170071EF-3D1F-4AB7-B6C8-743CA496C070 Q35552376-36162A93-8F3F-4BC4-BE0C-121DBBB77EC3 Q35585465-37A5B438-5753-43EC-AC29-0B46B4324B63 Q35683116-3C16C62C-76A2-4F26-A952-52389C4BFD3B Q36054625-694890EA-9342-499B-AFF7-0449DB56BBA2 Q36109785-E5B3CF65-62F3-4E81-A516-CA83707BAE7D Q36153123-3C153A17-FF13-4344-A571-89AC02F9A37B Q36157136-E489B7E5-D144-4C0F-9407-8B8D4A6DA1B1 Q36545205-1DCB8056-F292-4569-B863-0890796C2B5A Q36909227-EA21697B-D3BC-4C32-A6BB-1E5447A793F9 Q36995781-FAA143FE-6B95-4895-BB37-D5C732286440 Q37060946-4DE16F28-B0A1-440B-B2F3-274F73F1EAD7 Q37339044-9369370E-E424-40A8-8EAE-86C13847C975 Q37405633-9FAA296E-5BF5-4807-9F16-88A2571736B6 Q37406548-41EC40E1-8F8D-4DD9-A638-9691509A2654 Q37407102-54B3151C-B9E9-431F-A00B-FC99F83C5785 Q37437236-6B17AF55-7B1B-4950-800F-AF44F9E45071 Q37494943-54058C76-8EF9-465A-BE35-AEDD3B913D1A Q37515438-4E960F60-AF4A-4BCB-9D8E-2AF407633278 Q37565038-A01AC6A6-55FE-4D65-BFCC-756F4759B9B9 Q37711811-F1D86330-7575-4611-85B1-91A26ADE38DE Q37736496-5414A562-2E85-474E-8F28-26222162A236 Q37788246-157A1CBC-DA85-4B63-8D7A-ACEF54CABB48 Q37831351-EB70A23C-3070-4B5F-B6BA-F8675A667C87

P2860

Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma

http://www.wikidata.org/entity/Q39966334

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Combined inhibition of c-Src a ...... d neck squamous cell carcinoma

@en

Combined inhibition of c-Src a ...... neck squamous cell carcinoma.

@nl

type

label

Combined inhibition of c-Src a ...... d neck squamous cell carcinoma

@en

Combined inhibition of c-Src a ...... neck squamous cell carcinoma.

@nl

prefLabel

Combined inhibition of c-Src a ...... d neck squamous cell carcinoma

@en

Combined inhibition of c-Src a ...... neck squamous cell carcinoma.

@nl

P1433

Q39966334-98D9283B-42C1-4422-B1A7-9ECA1DD643D1

P1476

Q39966334-C2C13E7E-8A6C-4EC0-BDF2-D1209D7391DD

P2093

Q39966334-3913FD4C-49EF-4F95-95A7-17D45D102CF5

Q39966334-41DEC462-2505-4C94-8E73-B3F50FCD9A0A

Q39966334-AC54D1B1-93A0-48AE-AD15-6E63DCD88EA0

Q39966334-AE2C0F35-1544-40E3-A9F4-39DCC4B727E5

Q39966334-BB4E8F22-5634-4F2B-92D6-37112A091675

Q39966334-C4B85372-22AF-4745-8F83-83F59CA957C5

Q39966334-CB171988-FC10-4F7C-8CED-A45D05390E6B

Q39966334-DF619C93-4975-4E33-89D1-31FE6392E54C

Q39966334-F334DCD4-CBBA-4E82-95B5-AA3EF5F791AB

P2860

Q39966334-02A459E1-A90E-4AC9-9F8D-E7517752E198

Q39966334-0456064D-903E-4D82-9FE2-03B72E213E76

Q39966334-0700CA4D-405F-4B34-A682-0CF04D873A55

Q39966334-1322DF81-DD87-4FDB-9960-1A0C7E1FB8BD

Q39966334-14143055-A9D8-43DE-8672-E28013160039

Q39966334-14EC3ABF-598A-4DBC-9F03-D59C2963CA2D

Q39966334-183EB284-DFE6-4AEA-A50C-03AEC5F199EC

Q39966334-1C29C77B-8EB0-4C5D-B2AE-D4B6E232468D

Q39966334-1D0D0CD4-0250-4232-B0CA-7842CB112B98

Q39966334-21B832F5-F07A-4498-B895-0A3F1D063868

P304

Q39966334-97BE2DF1-DDD5-4362-926F-40C6A79B7D2C

P31

Q39966334-00873FF1-AA4A-49C0-85ED-CA5B6924B6A0

P356

Q39966334-213EA04E-24B4-4DAF-83A1-6920DD1B189E

P407

Q39966334-37B10520-58EF-4198-B47D-30831A5F8AAC

P433

Q39966334-E29B0663-DCB3-4D0F-AF0D-D8D8C2E9A10F

P478

Q39966334-6341D070-657F-4E72-ABAE-C9520F0D0449

P50

Q39966334-7D867260-D017-4574-9A59-9B27D7F501D6

Q39966334-B5C5EBBE-6EFE-45A7-8C85-F1C58980F0EA

P577

Q39966334-DC27DF70-A118-473C-A580-46A9B8A86217

P698

Q39966334-0697E937-769C-4597-B2FC-DEAA9D042289

P921

Q39966334-87470818-438E-4A3F-9228-36E139DD1403

P932

Q39966334-BB04139B-1C4B-42E6-A5BE-BD1674C1E1E8

P356

1078-0432.CCR-07-5226

P1433

Clinical Cancer Research

P1476

Combined inhibition of c-Src a ...... d neck squamous cell carcinoma

@en

P2093

Ann Marie Egloff

http://www.w3.org/2001/XMLSchema#string

Hiroshi Nozawa

http://www.w3.org/2001/XMLSchema#string

Jill M Siegfried

http://www.w3.org/2001/XMLSchema#string

Maria Freilino

http://www.w3.org/2001/XMLSchema#string

Priya Koppikar

http://www.w3.org/2001/XMLSchema#string

Quan Cai

http://www.w3.org/2001/XMLSchema#string

Seung-Ho Choi

http://www.w3.org/2001/XMLSchema#string

Shinsuke Suzuki

http://www.w3.org/2001/XMLSchema#string

William E Gooding

http://www.w3.org/2001/XMLSchema#string

P2860

Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer

Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.

CD44 interaction with c-Src kinase promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian tumor cell migration

Lack of mutation at codon 531 of SRC in advanced colorectal cancers from Italian patients

Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

The specificities of protein kinase inhibitors: an update

Structures of Src-family tyrosine kinases.

An EGF receptor/Ral-GTPase signaling cascade regulates c-Src activity and substrate specificity.

P304

4284-4291

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-07-5226

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Jennifer Grandis

P577

2008-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18594011

http://www.w3.org/2001/XMLSchema#string

P921

head and neck squamous cell carcinoma

P932

3428119

http://www.w3.org/2001/XMLSchema#string